[go: up one dir, main page]

ME02666B - Cefalosporin sa kateholskom grupom - Google Patents

Cefalosporin sa kateholskom grupom

Info

Publication number
ME02666B
ME02666B MEP-2016-246A MEP24616A ME02666B ME 02666 B ME02666 B ME 02666B ME P24616 A MEP24616 A ME P24616A ME 02666 B ME02666 B ME 02666B
Authority
ME
Montenegro
Prior art keywords
compound
cephalosporin
solvate
ester
pharmaceutically acceptable
Prior art date
Application number
MEP-2016-246A
Other languages
German (de)
English (en)
French (fr)
Inventor
Yasuhiro Nishitani
Kenji Yamawaki
Yusuke Takeoka
Hideki Sugimoto
Shinya Hisakawa
Toshiaki Aoki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02666(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of ME02666B publication Critical patent/ME02666B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (1)

  1. Jedinjenje formule:ili njegov estar, zaštićeno jedinjenje na amino grupi u prstenu u bočnom nizu u položaju 7, njegova farmaceutski prihvatljiva so ili solvat.
    Farmaceutska smeša naznačena time što sadrži jedinjenje ili njegov estar, zaštićeno jedinjenje na amino grupi u prstenu u bočnom nizu u položaju 7, njegova farmaceutski prihvatljiva so ili solvat, prema patentnom zahtevu 1.
    Farmaceutska smeša prema patentnom zahtevu 2, naznačena time što je za upotrebu u lečenju antimikrobne infekcije.
    Jedinjenje ili njegov estar, zaštićeno jedinjenje na amino grupi u prstenu u bočnom nizu u položaju 7, njegova farmaceutski prihvatljiva so ili solvat, prema patentnom zahtevu 1 , naznačeno time što je za upotrebu u lečenju zarazne bolesti.
MEP-2016-246A 2008-10-31 2009-10-27 Cefalosporin sa kateholskom grupom ME02666B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
EP15175084.1A EP2960244B1 (en) 2008-10-31 2009-10-27 Cephalosporin having catechol group

Publications (1)

Publication Number Publication Date
ME02666B true ME02666B (me) 2017-06-20

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-246A ME02666B (me) 2008-10-31 2009-10-27 Cefalosporin sa kateholskom grupom

Country Status (38)

Country Link
US (1) US9238657B2 (me)
EP (2) EP2960244B1 (me)
JP (2) JP5498393B2 (me)
KR (1) KR101655961B1 (me)
CN (1) CN102203100B (me)
AU (1) AU2009310959B2 (me)
BR (1) BRPI0921701B8 (me)
CA (1) CA2736953C (me)
CL (1) CL2011000939A1 (me)
CO (1) CO6331443A2 (me)
CR (1) CR20110144A (me)
CY (2) CY1118536T1 (me)
DK (1) DK2960244T3 (me)
EA (1) EA019520B1 (me)
ES (2) ES2564836T3 (me)
FI (1) FIC20200039I1 (me)
FR (1) FR20C1050I2 (me)
HR (1) HRP20161408T1 (me)
HU (2) HUE031802T2 (me)
IL (1) IL211720A (me)
LT (2) LT2960244T (me)
MA (1) MA32731B1 (me)
ME (1) ME02666B (me)
MX (1) MX2011004636A (me)
MY (1) MY155655A (me)
NL (1) NL301067I2 (me)
NO (1) NO2020035I1 (me)
NZ (1) NZ591728A (me)
PE (1) PE20120010A1 (me)
PL (1) PL2960244T3 (me)
PT (1) PT2960244T (me)
RS (1) RS55365B1 (me)
SI (1) SI2960244T1 (me)
SM (1) SMT201600397B (me)
TW (1) TWI535727B (me)
UA (1) UA105190C2 (me)
WO (1) WO2010050468A1 (me)
ZA (1) ZA201102024B (me)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702257C (en) 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
ME02666B (me) 2008-10-31 2017-06-20 Shionogi & Co Cefalosporin sa kateholskom grupom
AU2011236933A1 (en) * 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
WO2011125966A1 (ja) * 2010-04-05 2011-10-13 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
US9085589B2 (en) 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative
WO2012121973A1 (en) * 2011-03-04 2012-09-13 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
EP2703406A4 (en) * 2011-04-28 2015-08-05 Shionogi & Co NOVEL CEPHEM COMPOUND HAVING THE CATÉCHOL STRUCTURE OR A STRUCTURE CLOSE TO CATÉCHOL
US9242999B2 (en) 2011-06-27 2016-01-26 Shionogi & Co., Ltd. Cephem compound having pyridinium group
TWI547496B (zh) 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (ja) 2011-10-04 2013-04-11 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
RU2015120084A (ru) 2012-10-29 2016-12-27 Сионоги Энд Ко., Лтд. Способы получения промежуточных соединений для 2-алкилцефемовых соединений
WO2014104148A1 (ja) * 2012-12-26 2014-07-03 塩野義製薬株式会社 セフェム化合物
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
UA121383C2 (uk) 2014-03-24 2020-05-25 Новартіс Аг Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016035847A1 (ja) * 2014-09-04 2016-03-10 塩野義製薬株式会社 セファロスポリン誘導体の中間体およびその製造方法
WO2016035846A1 (ja) * 2014-09-04 2016-03-10 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
MY178017A (en) * 2014-09-04 2020-09-29 Shionogi & Co A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
CN108137573B (zh) 2015-09-23 2021-06-11 诺华股份有限公司 单环内酰胺抗生素的盐和固体形式
EA039648B1 (ru) * 2015-12-10 2022-02-21 НАЕДЖА-АрДжиЭм ФАРМАСЬЮТИКАЛЗ ЮЭлСи Соединения цефема, их получение и применение
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
US20200316083A1 (en) * 2016-06-17 2020-10-08 Wockhardt Limited Antibacterial compositions
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US10933051B2 (en) * 2017-06-09 2021-03-02 Fob Synthesis, Inc. Carbapenem compounds and compositions for the treatment of bacterial infections
CA3063649A1 (en) 2017-08-02 2019-02-07 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof
CR20200372A (es) 2018-02-28 2020-10-26 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi8,9,9a,10-tetrahidro-7h-pirrolo (1`, 2`:4-5) pirazino (1,2-b) piridazina-3, 5-diona y compuestos relacionados como inhibidores de la replicación del ortomixo virus para el tratamiento de la influenza
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
CA3147354A1 (en) 2019-09-06 2021-03-11 Rosemarie Riedl Siderophore cephalosporin conjugates and uses thereof
US20230121689A1 (en) * 2020-01-22 2023-04-20 Shanghai Senhui Medicine Co., Ltd. Cephalosporin antibacterial compound and pharmaceutical application thereof
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
WO2022152146A1 (zh) 2021-01-12 2022-07-21 上海森辉医药有限公司 一种头孢类抗菌化合物及其制备方法
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
TW202448477A (zh) * 2023-06-01 2024-12-16 大陸商江蘇恆瑞醫藥股份有限公司 一種包含頭孢類抗菌化合物的醫藥組成物
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638A (zh) * 2023-08-17 2023-11-17 济南大学 一种头孢地尔中间体的制备方法
CN117088764A (zh) * 2023-08-24 2023-11-21 济南大学 一种头孢地尔关键中间体的合成和后处理方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
AU2361184A (en) 1983-01-21 1984-07-26 Beecham Group Plc Disubstituted 6-penicillins and 7-cephalosporins
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
DE3688477T2 (de) 1985-03-01 1993-09-16 Takeda Chemical Industries Ltd Antibakterielle verbindungen, ihre herstellung und verwendung.
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE3687200T2 (de) * 1985-09-03 1993-05-27 Otsuka Kagaku Kk Cephalosporinderivate.
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
DE3750411T2 (de) 1986-04-14 1995-03-16 Banyu Pharma Co Ltd Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Präparate.
US5084453A (en) * 1986-04-14 1992-01-28 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vinyloxyimino aminothiazole cephalosporin derivatives
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5126336A (en) * 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
AU1694099A (en) 1997-12-26 1999-07-19 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds
MXPA03008639A (es) 2001-03-27 2005-03-07 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolinas.
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
US6713625B2 (en) 2002-05-23 2004-03-30 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cefditoren using the thioester of thiazolylacetic acid
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
JP2009530228A (ja) * 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
ME02666B (me) 2008-10-31 2017-06-20 Shionogi & Co Cefalosporin sa kateholskom grupom
WO2011125966A1 (ja) 2010-04-05 2011-10-13 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
AU2011236933A1 (en) 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
US9085589B2 (en) 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative

Also Published As

Publication number Publication date
HUS2000042I1 (hu) 2020-11-30
CR20110144A (es) 2011-09-09
KR20110090982A (ko) 2011-08-10
PT2960244T (pt) 2016-11-02
EA201170632A1 (ru) 2011-12-30
SMT201600397B (it) 2017-01-10
MA32731B1 (fr) 2011-10-02
EP2341053A1 (en) 2011-07-06
NL301067I1 (me) 2020-10-13
NZ591728A (en) 2012-12-21
MX2011004636A (es) 2011-06-20
FIC20200039I1 (fi) 2020-10-19
IL211720A0 (en) 2011-06-30
PL2960244T3 (pl) 2017-03-31
WO2010050468A1 (ja) 2010-05-06
FR20C1050I2 (fr) 2021-10-15
PE20120010A1 (es) 2012-02-07
CY1118536T1 (el) 2017-07-12
IL211720A (en) 2015-01-29
KR101655961B1 (ko) 2016-09-08
CY2020034I1 (el) 2020-11-25
JP2014065732A (ja) 2014-04-17
BRPI0921701B8 (pt) 2022-11-29
CA2736953A1 (en) 2010-05-06
UA105190C2 (ru) 2014-04-25
MY155655A (en) 2015-11-13
BRPI0921701B1 (pt) 2022-05-03
EP2341053B1 (en) 2016-01-13
EP2341053A4 (en) 2012-08-08
JPWO2010050468A1 (ja) 2012-03-29
ZA201102024B (en) 2014-08-27
US20110190254A1 (en) 2011-08-04
LT2960244T (lt) 2016-11-25
CL2011000939A1 (es) 2011-09-16
FR20C1050I1 (me) 2020-11-27
AU2009310959B2 (en) 2015-05-07
JP5498393B2 (ja) 2014-05-21
TWI535727B (zh) 2016-06-01
AU2009310959A1 (en) 2010-05-06
CN102203100B (zh) 2014-08-27
SI2960244T1 (sl) 2017-02-28
CA2736953C (en) 2017-07-11
HRP20161408T1 (hr) 2016-12-02
CN102203100A (zh) 2011-09-28
ES2564836T3 (es) 2016-03-29
DK2960244T3 (en) 2016-11-28
EP2960244A1 (en) 2015-12-30
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
TW201020259A (en) 2010-06-01
RS55365B1 (sr) 2017-03-31
EA019520B1 (ru) 2014-04-30
US9238657B2 (en) 2016-01-19
LTPA2020530I1 (lt) 2020-11-10
BRPI0921701A2 (pt) 2020-08-11
CY2020034I2 (el) 2021-05-05
EP2960244B1 (en) 2016-09-14
NO2020035I1 (no) 2020-10-21
HUE031802T2 (en) 2017-08-28
CO6331443A2 (es) 2011-10-20
ES2602969T3 (es) 2017-02-23

Similar Documents

Publication Publication Date Title
ME02666B (me) Cefalosporin sa kateholskom grupom
FI4219508T3 (fi) Substituoitu polysyklinen pyridonijohdannainen ja sen aihiolääke
HRP20171512T1 (hr) Derivati betulina
ME02558B (me) Inhibitori replikacije virusa gripa
HRP20151000T1 (hr) Antivirusni spojevi
HRP20171175T1 (hr) Novi triciklički spojevi
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
HRP20161103T1 (hr) Kemijski spojevi
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
AR062392A1 (es) Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de rosacea
CR11208A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
EA201391325A1 (ru) Новые производные цефалоспорина и их фармацевтические композиции
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
JP2011527299A5 (me)
WO2010129057A3 (en) Tetracycline compounds
WO2008143649A3 (en) Novel oxazolidinone compounds as antiinfective agents
WO2011025982A3 (en) Tetracycline compounds
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
BR112015004523A2 (pt) compostos de tetraciclina
ME02405B (me) Spojevi pirazola као inhibitori sglt1